Roflumilast with long-acting β 2-agonists for COPD: Influence of exacerbation history

European Respiratory Journal

Volumn 38, Issue 3, 2011, Pages 553-560

  Bateman, E D ^a   Rabe, K F ^b,c   Calverley, P M A ^e   Goehring, U M ^d   Brosee, M ^d   Bredenbroker D ^d   Fabbri, L M ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF KIEL   (Germany)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d Nycomed GmbH   (Germany)

^e UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Dyspnoea; Exacerbation; Lung function; Roflumilast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL;

ADULT; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AMINOPYRIDINES; BENZAMIDES; BRONCHODILATOR AGENTS; CYCLOPROPANES; DYSPNEA; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS;

EID: 79957513424     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00178710     Document Type: Article

References (28)

1. Bourbeau J, Ford G, Zackon H, et al. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007; 30: 907-913. (Pubitemid 351194794)
2. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224-1238. (Pubitemid 46895385)
3. Xu W, Collet JP, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010; 35: 1022-1030.
4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (updated 2010). http://www. goldcopd.org/Guidelineitem.asp?l1=2&l2= 1&intId=989 Date last updated: December 2010.
5. Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 1: CD002733.
6. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009; 29: 891-905.
7. Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009; 7: 2.
8. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a oncedaily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317-326.
9. Agarwal R, Aggarwal AN, Gupta D, et al. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010; 137: 318-325.
10. Giembycz MA. An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 2006; 62: 138-152. (Pubitemid 44316425)
11. Woyda K, Koebrich S, Reiss I, et al. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J 2009; 33: 861-870.
12. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008; 155: 288-290.
13. Vestbo J, Tan L, Atkinson G, et al. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009; 33: 1039-1044.
14. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081-1087. (Pubitemid 350206202)
15. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010; 23: 235-256.
16. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154-161. (Pubitemid 47057851)
17. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-571. (Pubitemid 41140331)
18. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
19. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
20. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Series in Statistics XXII. New York, Springer, 2000.
21. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
22. Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30: 993-1013. (Pubitemid 351194805)
23. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-982.
24. Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, et al. Case-fatality of COPD exacerbations: a meta-analysis and statistical modeling approach. Eur Respir J 2011; 37: 508-515.
25. Silverman EK. Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc Am Thorac Soc 2007; 4: 586-590. (Pubitemid 350291618)
26. National Institute for Clinical Excellence. Clinical Guideline 12: Chronic Obstructive Pulmonary Disease. Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London, National Institute for Clinical Excellence, 2004.
27. Engelstatter R, Wingertzahn M, Schmid-Wirlitsch C, et al. Roflumilast, an oral once-daily phosphodiesterase 4 (PDE4) inhibitor does not exhibit bronchodilator activity. Ann Allergy Asthma Immunol 2005; 94: 169.
28. Grootendorst DC, Gauw SA, Benschop N, et al. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther 2003; 16: 341-347. (Pubitemid 37315858)